Pharma executives slam Europe's patent regime, while praising the US approach

Europe significantly lags the United States in terms of its regulatory and IP regimes for companies in the life sciences industries, according to respondents to a survey published today by Marks & Clerk. 
The EU's perceived hostility to the way in…

Get unlimited access to all IAM content